GHRP-2 Peptide 5mg

Buy 1 Get 1 Free - 5mg GHRP-2 Peptide:

Growth Hormone Releasing Peptide-2 (GHRP-2) is a synthetic analog of ghrelin, a peptide that naturally binds to the growth hormone secretagogue receptor (GHS-R) in the gastrointestinal system. Ghrelin promotes the release of growth hormone (GH) and stimulates appetite.¹ Similarly, GHRP-2 binds to GHS-R, triggering GH release. Both ghrelin and GHRP-2 impact the secretion of prolactin, cortisol, and corticotropin from the anterior pituitary.² This product is intended strictly for in vitro laboratory research only and consists of six amino acids, with a molecular weight of 818 Da. While chemically distinct from ghrelin, GHRP-2 replicates many of ghrelin’s biological activities for laboratory research purposes.³

Mechanisms of GHRP-2 in Enhancing Growth Hormone

GHRP-2 aids in increasing natural GH levels through two primary mechanisms:

• Amplification of Endogenous Signals: By binding to GHS-R, GHRP-2 significantly boosts growth hormone release. Laboratory research shows that GHRP-2 stimulates GH release even in subjects with genetic mutations impacting natural GHRH production.⁴
• Suppression of Somatostatin: GHRP-2 inhibits somatostatin, a hormone that decreases GH release, thereby enhancing GH levels.⁵

In laboratory studies, GHRP-2 has shown synergy with growth hormone-releasing factor (GRF), facilitating GH release from the pituitary in research models.⁵ Animal and human research also suggests that GHRP-2 can increase food intake.^3,6

Potential Research Applications of GHRP-2

• Muscle Growth: GHRP-2 has been associated with potential applications in muscle growth studies.⁷
• Immune Response: Research indicates possible enhancements in immune response with GHRP-2.⁸
• Sleep Studies: Evidence suggests GHRP-2 may improve sleep quality, making it relevant for sleep physiology research.⁹
• Cardiovascular Health: GHRP-2 shows potential protective effects on cardiovascular health in research settings.¹⁰
• IGF-I Release: GHRP-2 has been shown to increase the release of insulin-like growth factor I (IGF-I), valuable in growth-related studies.¹¹

Additionally, a study observed that intraperitoneal injection of GHRP-2 reduced tissue necrotic factor-alpha (TNF-α) in a rat model of liver damage, suggesting potential research applications in inflammation studies.¹²

Product Information

GHRP-2 is supplied as a lyophilized powder (5 mg per vial) exclusively for in vitro research use. The vial can be reconstituted with sterile water for laboratory applications.

Important Note: GHRP-2 is provided strictly for in vitro laboratory research only and is not approved for human or veterinary use. Any application outside of controlled research environments is strictly prohibited.

References

1. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4679-84.
2. Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr Rev. 2006 Apr;27(2):101-40.
3. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. Endocrinology. 2009 Dec;150(12):5478-87.
4. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005 Feb;90(2):611-4.
5. Cheng J, Wu TJ, Butler B, Cheng K. Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci. 1997;60(16):1385-92.
6. Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab. 2003 Sep;16(7):981-5.
7. Hu R, Wang Z, Peng Q, Zou H, Wang H, Yu X, Jing X, Wang Y, Cao B, Bao S, Zhang W, Zhao S, Ji H, Kong X, Niu Q. Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation. PLoS One. 2016 Feb 19;11(2):e0149461.
8. Taub DD, Murphy WJ, Longo DL. Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways. Curr Opin Pharmacol. 2010 Aug;10(4):408-24.
9. Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 Oct;66(4):278-86.
10. Muccioli G, Broglio F, Valetto MR, Ghè C, Catapano F, Graziani A, Papotti M, Bisi G, Deghenghi R, Ghigo E. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris). 2000 Feb;61(1):27-31.
11. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004 May;89(5):2290-300.

Click here to read more about GHRP-2 peptide on our research blog.